Company:  ALLENA PHARMACEUTICALS, I ... (ALNA)
Form Type:  SC 13G/A
Filing Date:  2/14/2020 
CIK:  0001624658 
Address:  ONE NEWTON EXECUTIVE PARK
SUITE 202
 
City, State, Zip:  NEWTON, Massachusetts 02462 
Telephone:  617-467-4577 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$1.10  
Change: 
-0.04 (-3.51%)  
Trade Time: 
May 14  
Market Cap: 
$63.46M
Trade ALNA now with 

© 2021  
Description of Business
We are a late-stage, clinical biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. We are focused on metabolic disorders that result in excess accumulation of certain metabolites that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease, or ESRD. We believe our proprietary know-how in enzyme technology allows for the design, development, formulation, and scalable manufacturing of non-absorbed and stable enzymes delivered orally and in sufficient doses for activity in the gastrointestinal tract. This approach enables us to develop enzyme therapies that degrade metabolites within the GI tract, which reduces potentially toxic metabolite levels in the blood and urine, and in turn, diminishes the disease burden including on the kidney over time.
Register and access this filing in:     
  FORM SC 13G/A